Stereotactic body radiation therapy for adrenal gland metastases: A multi-institutional outcome analysis

被引:1
作者
Yuste, C. [1 ,15 ]
Passerat, V. [2 ,3 ]
Calais, G. [3 ,4 ]
Schipman, B. [5 ]
Vaugier, L. [6 ]
Paumier, A. [1 ]
Huertas, A. [7 ]
Hemery, C. G. [8 ]
Debelleix, C. [9 ]
Chamois, J. [10 ]
Blanchard, N. [11 ]
Septans, AL. [12 ]
Pointreau, Y. [3 ,4 ,12 ,13 ,14 ]
机构
[1] Inst Cancerol Ouest, Angers, France
[2] Ctr Bayard, Villeurbanne, France
[3] Colib Club Oncologues Liberaux, Le Mans, France
[4] Oncol & Radiotherapie CORAD, Tours, France
[5] Inst Cancerol Bourgogne, Dijon, France
[6] Inst Cancerol Ouest, St Herblain, France
[7] Inst Radiotherapie Sud Oise, Creil, France
[8] Polyclin Courlancy, Reims, France
[9] Clin Bordeaux Tivoli Ducos, Bordeaux, France
[10] Private Hosp, Saint Gregoire, France
[11] Clin Dentellieres, Valenciennes, France
[12] Weprom, Angers, France
[13] Ctr Jean Bernard, Inst Interreg Cancerol ILC, Le Mans, France
[14] Ctr Cancerol Sarthe CCS, Le Mans, France
[15] Inst Cancerol Ouest, 15 Rue Andre Boquel, F-49055 Angers, France
关键词
Stereotactic body radiation therapy; Oligometastasis; Adrenal gland; Local control; Survival; Prognostic factors; OLIGOMETASTASES; CRITERIA;
D O I
10.1016/j.ctro.2023.100708
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Aim: The adrenal gland is a common site of metastasis with a rate of up to 27% in autopsy series. The incidence of these metastases is increasing due to greater use of Positron Emission Tomography scans and improved overall survival of patients with metastatic cancers. Stereotactic body radiation therapy (SBRT) is a non-invasive treatment option for metastasis. The aim of this study is to assess prognostic factors influencing local control, progression-free and overall survival in oligometastatic patients treated with SBRT for an adrenal metastasis. Methods: In this multicentric retrospective study, we included patients with adrenal metastases treated with SBRT between 2010 and 2021 in eleven french centers. All primary tumors were included. Results: A total of 110 patients treated for 121 adrenal lesions were included. Non-small-cell lung cancer was the predominant histologic type (55.4 %). Eighty-two percent of patients had at least 2 metastatic sites. The median Planning Target Volume was 70 cm3 with a median prescription dose of 40 Gray (Gy). The mean Biologically Effective Dose (BED) 10 dose was 74.2 Gy. Local control at 1 and 2 years was 85.9 % and 72.5 % respectively. The median overall survival and progression-free survival were 31.6 and 8.5 months respectively. Local control was significantly improved by systemic treatment one month before or after SBRT (p = 0.009) and by a BED10 greater than or equal to 50 Gy (p = 0.003). In multivariate analysis, oligometastatic presentation (p = 0.009) and a metachronous metastatic presentation (p = 0.008) were independent factors for progression-free survival. Tolerance was excellent, no grade 3 and 4 toxicities were described due to SBRT. Conclusion: Stereotactic radiotherapy of adrenal metastases makes possible a local control of more than 85% at one year and was well tolerated. The factors influencing survival in oligometastatic patients still need to be found in order to better select those who benefit the most from this type of treatment.
引用
收藏
页数:8
相关论文
共 50 条
  • [11] Robotic stereotactic body radiotherapy for the management of adrenal gland metastases: a bi-institutional analysis
    Ehret, Felix
    Kaul, David
    Kufeld, Markus
    Vom Endt, Clara
    Budach, Volker
    Senger, Carolin
    Fuerweger, Christoph
    Haidenberger, Alfred
    Muacevic, Alexander
    [J]. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2023, 149 (03) : 1095 - 1101
  • [12] Robotic stereotactic body radiotherapy for the management of adrenal gland metastases: a bi-institutional analysis
    Felix Ehret
    David Kaul
    Markus Kufeld
    Clara vom Endt
    Volker Budach
    Carolin Senger
    Christoph Fürweger
    Alfred Haidenberger
    Alexander Muacevic
    [J]. Journal of Cancer Research and Clinical Oncology, 2023, 149 : 1095 - 1101
  • [13] Stereotactic Body Radiation Therapy for Liver Metastases
    Krug, David
    Blanck, Oliver
    Boda-Heggemann, Judit
    Dunst, Juergen
    [J]. ZENTRALBLATT FUR CHIRURGIE, 2019, 144 (03): : 242 - 251
  • [14] Multi-institutional analysis of extracranial oligometastatic colorectal cancer patients treated with stereotactic body radiation therapy: TROD 02-008 study
    Guler, Ozan Cem
    Hurmuz, Pervin
    Atalar, Banu
    Guney, Yildiz
    Saglam, Esra Kaytan
    Akyurek, Serap
    Bolukbasi, Yasemin
    Gural, Zeynep
    Tugrul, Fuzuli
    Korcum, Aylin
    Sen, Cenk Ahmet
    Yildirim, Berna Akkus
    Oksuz, Didem Colpan
    Kurt, Meral
    Guzeloz, Zeliha
    Aksu, Gorkem
    Saynak, Mert
    Aksu, Gamze
    Onal, Cem
    [J]. STRAHLENTHERAPIE UND ONKOLOGIE, 2024, 200 (11) : 958 - 966
  • [15] Stereotactic body radiation therapy (SBRT) of adrenal gland metastases in oligometastatic and oligoprogressive disease
    Reshko, Leonid B.
    Gaskins, Jeremy T.
    Silverman, Craig L.
    Dunlap, Neal E.
    [J]. REPORTS OF PRACTICAL ONCOLOGY AND RADIOTHERAPY, 2021, 26 (03) : 325 - 340
  • [16] Multi-institutional dose-segmented dosiomic analysis for predicting radiation pneumonitis after lung stereotactic body radiation therapy
    Adachi, Takanori
    Nakamura, Mitsuhiro
    Shintani, Takashi
    Mitsuyoshi, Takamasa
    Kakino, Ryo
    Ogata, Takashi
    Ono, Tomohiro
    Tanabe, Hiroaki
    Kokubo, Masaki
    Sakamoto, Takashi
    Matsuo, Yukinori
    Mizowaki, Takashi
    [J]. MEDICAL PHYSICS, 2021, 48 (04) : 1781 - 1791
  • [17] Stereotactic Body Radiation Therapy (SBRT) for Spinal Metastases Real-world Outcomes From an International Multi-institutional SBRT Registry
    Singh, Raj
    Valluri, Anisha
    Jenkins, Jan
    Davis, Joanne
    Vargo, John A.
    Sharma, Sanjeev
    [J]. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2022, 45 (05): : 196 - 201
  • [18] A Multi-Institutional Experience of MR-Guided Liver Stereotactic Body Radiation Therapy
    Rosenberg, Stephen A.
    Henke, Lauren E.
    Shaverdian, Narek
    Mittauer, Kathryn
    Wojcieszynski, Andrzej P.
    Hullett, Craig R.
    Kamrava, Mitchell
    Lamb, James
    Cao, Minsong
    Green, Olga L.
    Kashani, Rojano
    Paliwal, Bhudatt
    Bayouth, John
    Harari, Paul M.
    Olsen, Jeffrey R.
    Lee, Percy
    Parikh, Parag J.
    Bassetti, Michael
    [J]. ADVANCES IN RADIATION ONCOLOGY, 2019, 4 (01) : 142 - 149
  • [19] Safety and efficacy of stereotactic body radiotherapy as primary treatment for vertebral metastases: a multi-institutional analysis
    Guckenberger, Matthias
    Mantel, Frederick
    Gerszten, Peter C.
    Flickinger, John C.
    Sahgal, Arjun
    Letourneau, Daniel
    Grills, Inga S.
    Jawad, Maha
    Fahim, Daniel K.
    Shin, John H.
    Winey, Brian
    Sheehan, Jason
    Kersh, Ron
    [J]. RADIATION ONCOLOGY, 2014, 9 : 226
  • [20] Phase II trial of stereotactic body radiation therapy on adrenal gland metastases: evaluation of efficacy and impact on hormonal production
    Franzese, Ciro
    Stefanini, Sara
    Massaro, Maria
    Comito, Tiziana
    Navarria, Pierina
    Clerici, Elena
    Teriaca, Ausilia
    Franceschini, Davide
    Reggiori, Giacomo
    Tomatis, Stefano
    Lania, Andrea
    Scorsetti, Marta
    [J]. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2021, 147 (12) : 3619 - 3625